HERV-K activation is strictly required to sustain CD133+ melanoma cells with stemness features

Journal of Experimental and Clinical Cancer Research

Volumn 36, Issue 1, 2017, Pages

  Argaw Denboba, Ayele ^a   Balestrieri, Emanuela ^a   Serafino, Annalucia ^b   Cipriani, Chiara ^a   Bucci, Ilaria ^a   Sorrentino, Roberta ^a   Sciamanna, Ilaria ^c   Gambacurta, Alessandra ^a   Sinibaldi Vallebona, Paola ^a,b   Matteucci, Claudia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer stem cell; CD133; HERV K; Melanoma; Microenvironment; Retroelements

Indexed keywords

CD133 ANTIGEN; EFAVIRENZ; NEVIRAPINE; PROM1 PROTEIN, HUMAN;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL EXPANSION; CELL MIGRATION; CELL SELF-RENEWAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; ENDOGENOUS RETROVIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN ENDOGENOUS RETROVIRUS TYPE K; MELANOMA; MELANOMA CELL LINE; NONHUMAN; PHENOTYPE; RNA INTERFERENCE; TUMOR INVASION; TUMOR MICROENVIRONMENT; VIRUS ACTIVATION; VIRUS EXPRESSION; CANCER STEM CELL; CELL MOTION; CYTOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

AC133 ANTIGEN; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; ENDOGENOUS RETROVIRUSES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MELANOMA; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT; VIRUS ACTIVATION;

EID: 85010716519     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-016-0485-x     Document Type: Article

References (59)

1. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120:41-50. PubMed. Google Scholar.
2. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells-what challenges do they pose? Nat Rev Drug Discov. 2014;13:497-512. PubMed. Google Scholar.
3. Shakhova O, Sommer L. Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. Cancer Lett. 2013;338:74-81. PubMed. Google Scholar.
4. Zimmerer RM, Korn P, Demougin P, Kampmann A, Kokemüller H, Eckardt AM, et al. Functional features of cancer stem cells in melanoma cell lines. Cancer Cell Int. 2013;13:78. PubMed. Google Scholar.
5. Yu X, Lin Y, Yan X, Tian Q, Li L, Lin EH. CD133, Stem Cells, and Cancer Stem Cells: Myth or Reality? Curr Colorectal Cancer Rep. 2011;7:253-9. PubMed. Google Scholar.
6. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007;43:935-46. PubMed. Google Scholar.
7. Girouard SD, Murphy GF. Melanoma stem cells: not rare, but well done. Lab Invest. 2011;91:647-64. PubMed. Google Scholar.
8. Lai CY, Schwartz BE, Hsu MY. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res. 2012;72:5111-8. PubMed. Google Scholar.
9. Adini A, Adini I, Ghosh K, Benny O, Pravda E, Hu R, et al. The stem cell marker prominin-1/CD133 interacts with vascular endothelial growth factor and potentiates its action. Angiogenesis. 2013;16:405-16. PubMed. Google Scholar.
10. El-Khattouti A, Selimovic D, Haïkel Y, Megahed M, Gomez CR, Hassan M. Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response. Cancer Lett. 2014;343:123-33. PubMed. Google Scholar.
11. Rappa G, Fodstad O, Lorico A. The Stem CellAssociated Antigen CD133 (Prominin1) Is a Molecular Therapeutic Target for Metastatic Melanoma. Stem Cells. 2008;26:3008-17. PubMed. Google Scholar.
12. AbdusSamad M, Gaur A, Zhou H, Zapas JL, Simbulan-Rosenthal CM, McCarron EC, et al. CD133 knockdown sensitizes melanoma to kinase inhibitors. Cancer Res. 2015;15 Suppl 75:4224. Google Scholar.
13. Van den Hurk K, Niessen H, Veeck J, Van den Oord JJ, Van Steensel M, Zur Hausen A, et al. Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim Biophys Acta. 2012;1826:89-102. PubMed. Google Scholar.
14. Hook KS, Goding CR. Cancer stem cells versus phenotypeswitching in melanoma. Pigment Cell Melanoma Res. 2010;23:746-59. PubMed. Google Scholar.
15. Magiorkinis G, Belshaw R, Katzourakis A. 'There and back again': revisiting the pathophysiological roles of human endogenous retroviruses in the post-genomic era. Philos Trans R Soc Lond B Biol Sci. 2013;368:20120504. PubMed. Google Scholar.
16. Göke J, Ng HH. CTRL+ INSERT: retrotransposons and their contribution to regulation and innovation of the transcriptome. EMBO Rep. 2016;17:1131-44. PubMed. Google Scholar.
17. Robbez-Masson L, Rowe HM. Retrotransposons shape species-specific embryonic stem cell gene expression. Retrovirology. 2015;12:45. PubMed. Google Scholar.
18. Okahara G, Matsubara S, Oda T, Sugimoto J, Jinno Y, Kanaya F. Expression analyses of human endogenous retroviruses (HERVs): tissue-specific and developmental stage-dependent expression of HERVs. Genomics. 2004;84:982-90. PubMed. Google Scholar.
19. Balestrieri E, Pica F, Matteucci C, Zenobi R, Sorrentino R, Argaw-Denboba A, et al. Transcriptional Activity of Human Endogenous Retroviruses in Human Peripheral Blood Mononuclear Cells. Biomed Res Int. 2015;2015:164529. PubMed. Google Scholar.
20. Balestrieri E, Arpino C, Matteucci C, Sorrentino R, Pica F, Alessandrelli R, et al. HERVs expression in autism spectrum disorders. PLoS One. 2012;7:e48831. PubMed. Google Scholar.
21. Balestrieri E, Pitzianti M, Matteucci C, D'Agati E, Sorrentino R, Baratta A, et al. Human endogenous retroviruses and ADHD. World J Biol Psychiatry. 2014;15:499-504. PubMed. Google Scholar.
22. Young GR, Stoye JP, Kassiotis G. Are human endogenous retroviruses pathogenic? An approach to testing the hypothesis. Bioessays. 2013;35:794-803. PubMed. Google Scholar.
23. Cegolon L, Salata C, Weiderpass E, Vineis P, Palù G, Mastrangelo G. Human endogenous retroviruses and cancer prevention: evidence and prospects. BMC Cancer. 2013;13:4. PubMed. Google Scholar.
24. Downey RF, Sullivan FJ, Wang-Johanning F, Ambs S, Giles FJ, Glynn SA. Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice? Int J Cancer. 2015;137:1249-57. PubMed. Google Scholar.
25. Hohn O, Hanke K, Bannert N. HERV-K(HML-2), the best preserved family of HERVs: endogenization, expression, and implications in health and disease. Front Oncol. 2013;3:246. PubMed. Google Scholar.
26. Serafino A, Balestrieri E, Pierimarchi P, Matteucci C, Moroni G, Oricchio E, et al. The activation of human endogenous retrovirus K(HERV-K) is implicated in melanoma cell malignant transformation. Exp Cell Res. 2009;315:849-62. PubMed. Google Scholar.
27. Oricchio E, Sciamanna I, Beraldi R, Tolstonog GV, Schumann GG, Spadafora C. Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression. Oncogene. 2007;26:4226-33. PubMed. Google Scholar.
28. Schmitt K, Reichrath J, Roesch A, Meese E, Mayer J. Transcriptional profiling of human endogenous retrovirus group HERV-K (HML-2) loci in melanoma. Genome Biol Evol. 2013;5:307-28. PubMed. Google Scholar.
29. Reiche J, Pauli G, Ellerbrok H. Differential expression of human endogenous retrovirus K transcripts in primary human melanocytes and melanoma cell lines after UV irradiation. Melanoma Res. 2010;20:435-40. PubMed. Google Scholar.
30. Armbruester V, Sauter M, Roemer K, Best B, Hahn S, Nty A, et al. Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X. J Virol. 2004;78:10310-9. PubMed. Google Scholar.
31. Fuchs NV, Loewer S, Daley GQ, Izsvák Z, Lower J, Lower R. Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells. Retrovirology. 2013;10:115. PubMed. Google Scholar.
32. Krone B, Kölmel KF, Henz BM, Grange JM. Protection against melanoma by vaccination with bacilleCalmette-Guérin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer. 2005;41:104-17. PubMed. Google Scholar.
33. Mangeney M, Pothlichet J, Renard M, Ducos B, Heidmann T. Endogenous retrovirus expression is required for murine melanoma tumor growth in vivo. Cancer Res. 2005;65:2588-91. PubMed. Google Scholar.
34. Dong J, Huang G, Imtiaz R, Xu F. The Potential Importance of K Type Human Endogenous Retroviral Elements in Melanoma Biology. INTECH Open Access Publisher 2013; DOI: 10.5772/55264. Article. Google Scholar
35. Huang G, Li Z, Wan X, Wang Y, Dong J. Human endogenous retroviral K element encodes fusogenic activity in melanoma cells. J Carcinog. 2013;12:5. PubMed. Google Scholar.
36. Wang AX, Qi XY. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. IUBMB Life. 2013;65:748-58. PubMed. Google Scholar.
37. Melino G, Sinibaldi-Vallebona P, D'Altri S, Annichiarico-Petruzzelli M, Rasi G, Catani MV, et al. Characterization of three melanoma cell lines (TVM-A12, TVM-A197, TVM-BO) sensitivity to lysis and effect of retinoic acid. Clin Chem Enzymol Commun. 1993;6:105-19. Google Scholar.
38. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004;101:14228-33. PubMed. Google Scholar.
39. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797-806. PubMed. Google Scholar.
40. Wouters J, Stas M, Gremeaux L, Govaere O, Maes H, Agostinis P, et al. The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. PLoS One. 2013;8:e76550. PubMed. Google Scholar.
41. Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C, Beraldi R, et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene. 2005;24:3923-31. PubMed. Google Scholar.
42. Kurnick JT, Ramirez-Montagut T, Boyle LA, Andrews DM, Pandolfi F, Durda PJ, et al. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J Immunol. 2001;167:1204-11. PubMed. Google Scholar.
43. Mendez R, Aptsiauri N, Del Campo A, Maleno I, Cabrera T, Ruiz-Cabello F, et al. HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother. 2009;58:1507-15. PubMed. Google Scholar.
44. Hamaï A, Meslin F, Benlalam H, Jalil A, Mehrpour M, Faure F, et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res. 2008;68:9854-64. PubMed. Google Scholar.
45. Oba J, Nakahara T, Hashimoto-Hachiya A, Liu M, Abe T, Hagihara A, et al. CD10-Equipped Melanoma Cells Acquire Highly Potent Tumorigenic Activity: A Plausible Explanation of Their Significance for a Poor Prognosis. PLoS One. 2016;11:e0149285. PubMed. Google Scholar.
46. Liu W, Vivian CJ, Brinker AE, Hampton KR, Lianidou E, Welch DR. Microenvironmental influences on metastasis suppressor expression and function during a metastatic cell's journey. Cancer Microenviron. 2014;7:117-31. PubMed. Google Scholar.
47. Fofaria NM, Srivastava SK. Critical role of STAT3 in melanoma metastasis through anoikis resistance. Oncotarget. 2014;5:7051-64. PubMed. Google Scholar.
48. Löwer R, Löwer J, Kurth R. The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci U S A. 1996;93:5177-84. PubMed. Google Scholar.
49. Li FZ, Dhillon AS, Anderson RL, McArthur G, Ferrao PT. Phenotype switching in melanoma: implications for progression and therapy. Front Oncol. 2015;5:31. PubMed. Google Scholar.
50. Liao WT, Ye YP, Deng YJ, Bian XW, Ding YQ. Metastatic cancer stem cells: from the concept to therapeutics. Am J Stem Cells. 2014;3:46-62. PubMed. Google Scholar.
51. Liu A, Yu X, Liu S. Pluripotency transcription factors and cancer stem cells: small genes make a big difference. Chin J Cancer. 2013;32:483-7. PubMed. Google Scholar.
52. Zhou F, Li M, Wei Y, Lin K, Lu Y, Shen J, Johanning GL, Wang-Johanning F. Activation of HERV-K Env protein is essential for tumorigenesis and metastasis of breast cancer cells. Oncotarget. 2016 [Epub ahead of print] Aug 20. PubMed. Google Scholar
53. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009;28:209-18. PubMed. Google Scholar.
54. Wu X, Wu F, Xu D, Zhang T. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. J Neurooncol. 2016;127:221-32. PubMed. Google Scholar.
55. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics. 2009;1:239-59. PubMed. Google Scholar.
56. Stengel S, Fiebig U, Kurth R, Denner J. Regulation of human endogenous retrovirusK expression in melanomas by CpG methylation. Genes Chromosomes Cancer. 2010;49:401-11. PubMed. Google Scholar.
57. Sinibaldi-Vallebona P, Matteucci C, Spadafora C. Retrotransposon-encoded reverse transcriptase in the genesis, progression and cellular plasticity of human cancer. Cancers (Basel). 2011;3:1141-57. PubMed. Google Scholar.
58. Sciamanna I, Gualtieri A, Piazza PV, Spadafora C. Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression. Oncotarget. 2014;5:8039-51. PubMed. Google Scholar.
59. Sciamanna I, De Luca C, Spadafora C. The Reverse Transcriptase Encoded by LINE-1 Retrotransposons in the Genesis, Progression, and Therapy of Cancer. Front Chem. 2016;4:6. PubMed. Google Scholar.